Item 1. | |
(a) | Name of issuer:
Xilio Therapeutics, Inc. |
(b) | Address of issuer's principal executive
offices:
828 Winter Street, Suite 300 Waltham, Massachusetts, 02451 |
Item 2. | |
(a) | Name of person filing:
This statement is filed on behalf of AbbVie Inc. (the "Reporting Person") |
(b) | Address or principal business office or, if
none, residence:
The address of the Reporting Person is 1 North Waukegan Road, North Chicago, Illinois, 60064-6400. |
(c) | Citizenship:
The Reporting Person is organized under the laws of the State of Delaware. |
(d) | Title of class of securities:
Common Stock, par value $0.0001 per share |
(e) | CUSIP No.:
98422T100 |
Item 3. | If this statement is filed pursuant to §§
240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: |
(a) | Broker
or dealer registered under section 15 of the Act (15 U.S.C. 78o); |
(b) | Bank
as defined in section 3(a)(6) of the Act (15 U.S.C. 78c); |
(c) | Insurance
company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c); |
(d) | Investment
company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); |
(e) | An
investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E); |
(f) | An
employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F); |
(g) | A
parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G); |
(h) | A
savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.
1813); |
(i) | A
church plan that is excluded from the definition of an investment company under section 3(c)(14)
of the Investment Company Act of 1940 (15 U.S.C. 80a-3); |
(j) | A
non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S.
institution in accordance with § 240.13d-1(b)(1)(ii)(J), please
specify the type of institution: |
(k) | Group,
in accordance with Rule 240.13d-1(b)(1)(ii)(K). |
| |
Item 4. | Ownership |
(a) | Amount beneficially owned:
The information contained on the cover pages to this Schedule 13G is incorporated by reference into this Item 4.The ownership information presented herein represents beneficial ownership of the Common Stock as of the date hereof based upon 43,958,074 shares of Common Stock outstanding on November 1, 2024 according to the Issuer's Quarterly Report on Form 10-Q filed on November 7, 2024 and giving effect to the issuance of 4,347,826 shares of Common Stock to the Reporting Person on February 11, 2025. |
(b) | Percent of class:
9.0% % |
(c) | Number of shares as to which the person has:
|
| (i) Sole power to vote or to direct the vote:
4,347,826
|
| (ii) Shared power to vote or to direct the
vote:
0
|
| (iii) Sole power to dispose or to direct the
disposition of:
4,347,826
|
| (iv) Shared power to dispose or to direct the
disposition of:
0
|
Item 5. | Ownership of 5 Percent or Less of a Class. |
| |
Item 6. | Ownership of more than 5 Percent on Behalf of
Another Person. |
|
Not Applicable
|
Item 7. | Identification and Classification of the
Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or
Control Person. |
|
Not Applicable
|
Item 8. | Identification and Classification of Members of
the Group. |
|
Not Applicable
|
Item 9. | Notice of Dissolution of Group. |
|
Not Applicable
|